Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-103276
Filing Date
2026-03-12
Accepted
2026-03-12 10:00:59
Documents
95
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K mcrb-20251231.htm   iXBRL 10-K 4298640
2 EX-4.2 mcrb-ex4_2.htm EX-4.2 27708
3 EX-10.19 mcrb-ex10_19.htm EX-10.19 198008
4 EX-23.1 mcrb-ex23_1.htm EX-23.1 4235
5 EX-31.1 mcrb-ex31_1.htm EX-31.1 13261
6 EX-31.2 mcrb-ex31_2.htm EX-31.2 13592
7 EX-32.1 mcrb-ex32_1.htm EX-32.1 8938
8 EX-32.2 mcrb-ex32_2.htm EX-32.2 8511
  Complete submission text file 0001193125-26-103276.txt   16512331

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20251231.xsd EX-101.SCH 2422305
98 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20251231_htm.xml XML 2867671
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37465 | Film No.: 26746057
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)